E Fund CSI Innovative Drugs ETF(516080) falls 1.35%, with a net inflow of 78.3246 million yuan for five consecutive days

NewTimeSpace (newtimespace.com) News, as of 10:49 on June 3, 2026, E Fund Innovative Drug ETF (516080) fell 1.35%, with the latest price at 0.58 yuan. (The stocks listed above are only index constituents and do not constitute any specific recommendation.)

In terms of liquidity, E Fund Innovative Drug ETF recorded an intraday turnover rate of 1.77% and a trading volume of 29.9395 million yuan. Over a longer time frame, as of June 2, the ETF's average daily trading volume over the past week reached 79.7071 million yuan, ranking in the top 3 among comparable funds.

In terms of scale, E Fund Innovative Drug ETF saw a significant increase of 18.0274 million yuan in scale over the past week, with the new scale increase ranking 1/7 among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of E Fund Innovative Drug ETF reached 2.870 billion units, hitting a one-year high and ranking 3/7 among comparable funds. (Data source: Wind)

In terms of net capital inflow, E Fund Innovative Drug ETF saw consecutive net inflows for five days, with the highest single-day net inflow reaching 34.0136 million yuan. It attracted a total of 78.3246 million yuan, with an average daily net inflow of 15.6649 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of E Fund Innovative Drug ETF reached 3.0516 million yuan, with the latest margin financing balance standing at 37.9798 million yuan. (Data source: Wind)

As of June 2, the net value of E Fund Innovative Drug ETF rose by 17.67% over the past two years, ranking first among comparable funds. From the perspective of return capability, as of June 2, 2026, since its inception, the ETF achieved a highest single-month return of 22.96%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 33.43%, and an average return of 5.62% in up months. As of June 2, 2026, the ETF's annualized excess return over its benchmark for the past two years was 3.20%, ranking 1/7 among comparable funds.

In terms of drawdown, as of June 2, 2026, E Fund Innovative Drug ETF recorded a drawdown of 0.05% relative to its benchmark since the beginning of the year, reflecting lower drawdown risk among comparable funds.

In terms of fees, E Fund Innovative Drug ETF has a management fee rate of 0.15% and a custodian fee rate of 0.05%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of June 2, 2026, the one-month tracking error of E Fund Innovative Drug ETF was 0.062%, achieving relatively high tracking accuracy among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which E Fund Innovative Drug ETF tracks, is only 42.6 times, standing at the 4.17% percentile over the past year. This means the valuation is lower than over 95.83% of the time in the past year, placing it at a historical low.

E Fund Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.